Statin therapy and SAR-COV-2: an available and potential therapy?

Abdel-Latif, Rania G; Mohammed, Shaban; Elgendy, Islam Y

Abdel-Latif, Rania G; Mohammed, Shaban; Elgendy, Islam Y.

Abdel-Latif RG; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
Mohammed S; Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
Elgendy IY; Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Eur Heart J Cardiovasc Pharmacother ; 6(5): 333-334, 2020 09 01.

Article in English | MEDLINE | ID: covidwho-197914

Subject(s)

Antiviral Agents/therapeutic use; Betacoronavirus/drug effects; Coronavirus Infections/drug therapy; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Pneumonia, Viral/drug therapy; Animals; Betacoronavirus/immunology; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/immunology; Coronavirus Infections/virology; Host-Pathogen Interactions; Humans; Pandemics; Pneumonia, Viral/immunology; Pneumonia, Viral/virology; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Betacoronavirus Limits: Animals / Humans Language: English Journal: Eur Heart J Cardiovasc Pharmacother Year: 2020 Document Type: Article Affiliation country: Ehjcvp

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google